Abstract
Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM
Objectives
Candida auris is an emerging yeast pathogen with worldwide distribution and a great propensity for nosocomial spread. Recent reports have warned of the significant emergence of C. auris in several healthcare facilities. In order to stop its nosocomial transmission, use of antiseptics constitutes the first-line lever of action in fighting against C. auris skin colonization. However, little is known about the efficacy of these products, and moreover, no antiseptics are currently registered for use against C. auris.
Material and Methods
This study investigated the in vitro yeasticidal activity of povidone-iodine (Betadine®) against C. auris, and compared the findings to C. albicans and C. glabrata.
Results
In all the samples, the fungal load was substantially reduced by ≥4.2 Log10 colony-forming units, according to the EN standard 1275:2005. Moreover, even when largely diluted, povidone-iodine products still allowed a sustainable decrease of the yeast viability below 0.1%.
Conclusion
Overall, these results support the use of such commercial antiseptics in the context of colonization with this yeast.